NASDAQ:IOVA Iovance Biotherapeutics (IOVA) Stock Price, News & Analysis $14.62 +1.31 (+9.84%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$14.61 -0.01 (-0.08%) As of 10/9/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Iovance Biotherapeutics Stock (NASDAQ:IOVA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IOVA alerts:Sign Up Key Stats Today's Range$13.29▼$14.9450-Day Range$4.32▼$14.8252-Week Range$1.76▼$15.30Volume16.97 million shsAverage Volume19.43 million shsMarket Capitalization$6.62 billionP/E RatioN/ADividend YieldN/APrice Target$12.90Consensus RatingModerate Buy Company Overview Iovance Biotherapeutics, Inc. is a biotechnology company focused on developing and commercializing individualized cell therapies for patients with cancer. The company’s platform uses tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded in a manufacturing facility and reinfused to help the immune system recognize and attack cancer cells. Iovance’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved by the U.S. Food and Drug Administration for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment with a PD-1-blocking antibody and, when applicable, a BRAF-targeted therapy. Treatment involves collecting tumor tissue, expanding the patient’s TILs, administering a lymphodepleting chemotherapy regimen and reinfusing the expanded cells, followed by supportive interleukin-2 therapy. The company is also evaluating TIL-based therapies in additional solid tumors and cancer-treatment settings, including combination approaches designed to broaden the potential use of its cell therapy platform. Iovance, formerly known as Lion Biotechnologies, changed its name in 2017 and is headquartered in San Carlos, California. Its commercial activities are centered in the United States, while its development programs have involved clinical research conducted across multiple regions.AI Generated. May Contain Errors. Read More Iovance Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreIOVA MarketRank™: Iovance Biotherapeutics scored higher than 42% of companies evaluated by MarketBeat, and ranked 569th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingIovance Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on no strong buy ratings, 9 buy ratings, 3 hold ratings, and 1 sell rating.Downside RiskIovance Biotherapeutics has a consensus price target of $12.90, representing about 11.8% downside from its current price of $14.62.Amount of Analyst CoverageIovance Biotherapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Iovance Biotherapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Iovance Biotherapeutics are expected to grow in the coming year, from ($0.45) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Iovance Biotherapeutics is -20.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Iovance Biotherapeutics is -20.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIovance Biotherapeutics has a P/B Ratio of 8.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Iovance Biotherapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted15.52% of the float of Iovance Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverIovance Biotherapeutics has a short interest ratio ("days to cover") of 2.83, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Iovance Biotherapeutics has recently decreased by 25.60%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIovance Biotherapeutics does not currently pay a dividend.Dividend GrowthIovance Biotherapeutics does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.54 News SentimentIovance Biotherapeutics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Iovance Biotherapeutics this week, compared to 7 articles on an average week.Search Interest72 people have searched for IOVA on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows17 people have added Iovance Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 143% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Iovance Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders7.80% of the stock of Iovance Biotherapeutics is held by insiders.Percentage Held by Institutions77.03% of the stock of Iovance Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Iovance Biotherapeutics' insider trading history. Receive IOVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IOVA Stock News HeadlinesIovance Biotherapeutics (NASDAQ:IOVA) Shares Climb 6.6% After Analyst Upgrade4 hours ago | americanbankingnews.comIovance Biotherapeutics (NASDAQ:IOVA) Stock Price Expected to Rise, Robert W. Baird Analyst SaysOctober 10 at 2:18 AM | americanbankingnews.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.October 11 at 1:00 AM | Reagan Gold Group (Ad)Iovance Expands Lifileucel Into Sarcoma: What SARATOGA Means for InvestorsOctober 9 at 12:51 PM | tipranks.comIovance: Buy Now Before Many Growth Catalysts Kick InOctober 5, 2026 | seekingalpha.comWhy Iovance Biotherapeutics (IOVA) Effortlessly Soared 256% in Q3October 4, 2026 | finance.yahoo.comIovance Biotherapeutics (IOVA) Stock Gets Fair Value Boost On Amtagvi Demand And Margin OutlookOctober 3, 2026 | finance.yahoo.comIovance Biotherapeutics consensus price target increased by 34.74% to $13.06October 2, 2026 | msn.comSee More Headlines IOVA Stock Analysis - Frequently Asked Questions How have IOVA shares performed this year? Iovance Biotherapeutics' stock was trading at $2.73 at the beginning of the year. Since then, IOVA shares have increased by 435.5% and is now trading at $14.62. How were Iovance Biotherapeutics' earnings last quarter? Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) posted its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02. The firm's revenue was up 65.7% compared to the same quarter last year. Read the conference call transcript. Who are Iovance Biotherapeutics' major shareholders? Top institutional investors of Iovance Biotherapeutics include Mirador Capital Partners LP (0.24%), GAMMA Investing LLC, GK Wealth Management LLC and Farther Finance Advisors LLC. Insiders that own company stock include Merrill A Mcpeak, Raj K Puri and Ryan D Maynard. View institutional ownership trends. How do I buy shares of Iovance Biotherapeutics? Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Iovance Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Iovance Biotherapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), CrowdStrike (CRWD) and ServiceNow (NOW). Company Calendar Last Earnings8/06/2026Today10/11/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (8m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 IOVA's financial health is in the Green zone, according to TradeSmith. IOVA has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IOVA CIK1425205 Webwww.iovance.com Phone(650) 260-7120FaxN/AEmployees975Year Founded2013Price Target and Rating Average Price Target for Iovance Biotherapeutics$12.90 High Price Target$20.00 Low Price Target$7.00 Potential Upside/Downside-11.8%Consensus RatingModerate Buy Rating Score (0-4)2.62 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($0.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$390.98 million Net Margins-89.11% Pretax Margin-90.42% Return on Equity-40.51% Return on Assets-31.65% Debt Debt-to-Equity RatioN/A Current Ratio4.34 Quick Ratio3.82 Sales & Book Value Annual Sales$263.50 million Price / Sales25.13 Cash FlowN/A Price / Cash FlowN/A Book Value$1.76 per share Price / Book8.31Miscellaneous Outstanding Shares452,970,000Free Float417,639,000Market Cap$6.62 billion OptionableOptionable Beta0.76 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:IOVA) was last updated on 10/11/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
